⚕️ Medical Disclaimer
⚕️ Medical Disclaimer: Educational comparison only. NMN, NR, and NAD+ products are not FDA-approved longevity drugs. This is not a dosing protocol.
Three Different Things People Collapse Into One Word
NAD+ (nicotinamide adenine dinucleotide) is the redox coenzyme cells use for metabolism and for NAD+-consuming enzymes such as sirtuins and PARPs. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are oral precursors on biosynthetic pathways that can raise NAD+ metabolites. They are not interchangeable with an IV “NAD drip,” and none of them is a peptide.
CalcMyPeptide’s NMN leaf exists for precursor identity. The NAD+ leaf covers the coenzyme / clinic-folklore identity. This essay compares NMN vs NR vs NAD+ using sources we opened — not a second NMN leaf and not an NR peptide page that would 404.
Pathway Map Without the Marketing Fog
NR can be converted toward NMN and then toward NAD+ via salvage pathways. NMN sits one step closer to NAD+ on that map. Oral nicotinamide (Nam) uses salvage routes differently and behaves differently in short-term blood metabolome studies.
Raising a blood NAD+ reading is not the same as proving a longevity indication. Most human work measures circulating NAD+ metabolites, metabolic biomarkers, or short functional endpoints — not lifespan.
Head-to-Head Human Precursor Data We Opened
A randomized, open-label, placebo-controlled study published in Nature Metabolism (2025; ClinicalTrials.gov NCT05517122) compared oral NAD+ boosters in 65 healthy adults over 14 days. NR and NMN each increased circulatory NAD+ concentrations in healthy adults; chronic nicotinamide did not match that sustained pattern in the authors’ framing. Acute metabolome effects differed: only Nam produced a clear acute, transient whole-blood NAD+ metabolome bump in that report.
The same paper explores gut-microbial conversion of NR and NMN toward nicotinic acid and proposes a gut-dependent model for how NR/NMN elevate systemic NAD+ via the Preiss–Handler pathway, while Nam acts more through salvage. Treat the microbial model as the authors’ mechanistic proposal supported by their ex vivo work — not as proof that every capsule “needs” a specific microbiome.
Separate NMN RCTs we opened include Katayoshi et al. (Scientific Reports, 2023): 250 mg/day NMN for 12 weeks in healthy middle-aged adults raised NAD+ metabolism markers and was well tolerated; arterial-stiffness signals trended but did not reach a clear between-group win on pulse-wave velocity. Yi et al. (GeroScience, 2023) summarized dose-dependent NMN safety/efficacy work in middle-aged adults — useful for “oral NMN raises NAD-related markers in several designs,” not for claiming anti-aging drug status.
NMN vs NR vs NAD+ — Practical Distinctions
• NMN vs NR: In the opened Nestlé/Nature Metabolism head-to-head window, both oral NR and oral NMN raised circulatory NAD+ over two weeks in healthy adults. That does not mean every commercial product is bioequivalent. Formulation, dose, and assay method still dominate.
• Either precursor vs NAD+ itself: Oral NAD+ is a poor “just swallow the coenzyme” story in popular marketing. Clinic IV/SubQ NAD+ folklore is a different exposure and a different risk conversation — see the NAD+ leaf. Precursor capsules are not that.
• Peptides in the longevity aisle: Epitalon, MOTS-c, and SS-31 are separate mechanisms. Our NAD+ peptides longevity stack essay covers combination folklore; combination RCTs remain thin.
Evidence Limits (Read These Twice)
No opened source in this batch makes NMN or NR an FDA longevity drug. Regulatory status for NMN as a dietary ingredient has shifted by jurisdiction and year — this site tracks identity, not purchase advice.
Do not invent PMIDs or “50% NAD decline by age 60” factoids without a paper in hand. If a figure is not in an opened source, we omit it.
Community stacks that mix NMN with peptides, methylene blue, or “mitochondrial cocktails” are anecdote unless a specific co-administration trial exists.